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Abstract—The prognostic power of circulating cardiac biomarkers, their utility, and pattern of release in coronavirus disease 
2019 (COVID-19) patients have not been clearly defined. In this multicentered retrospective study, we enrolled 3219 
patients with diagnosed COVID-19 admitted to 9 hospitals from December 31, 2019 to March 4, 2020, to estimate the 
associations and prognostic power of circulating cardiac injury markers with the poor outcomes of COVID-19. In the 
mixed-effects Cox model, after adjusting for age, sex, and comorbidities, the adjusted hazard ratio of 28-day mortality for 
hs-cTnI (high-sensitivity cardiac troponin I) was 7.12 ([95% CI, 4.60–11.03] P<0.001), (NT-pro)BNP (N-terminal pro-B-
type natriuretic peptide or brain natriuretic peptide) was 5.11 ([95% CI, 3.50–7.47] P<0.001), CK (creatine phosphokinase)-
MB was 4.86 ([95% CI, 3.33–7.09] P<0.001), MYO (myoglobin) was 4.50 ([95% CI, 3.18–6.36] P<0.001), and CK was 
3.56 ([95% CI, 2.53–5.02] P<0.001). The cutoffs of those cardiac biomarkers for effective prognosis of 28-day mortality of 
COVID-19 were found to be much lower than for regular heart disease at about 19%–50% of the currently recommended 
thresholds. Patients with elevated cardiac injury markers above the newly established cutoffs were associated with 
significantly increased risk of COVID-19 death. In conclusion, cardiac biomarker elevations are significantly associated 
with 28-day death in patients with COVID-19. The prognostic  cutoff values of these biomarkers might be much lower 
than the current reference standards. These findings can assist in better management of COVID-19 patients to improve 
outcomes. Importantly, the newly established cutoff levels of COVID-19–associated cardiac biomarkers may serve as 
useful criteria for the future prospective studies and clinical trials.  (Hypertension. 2020;76:1104-1112. DOI: 10.1161/
HYPERTENSIONAHA.120.15528.) • Data Supplement
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The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection has led to >11.8 million confirmed 
cases with >545 000 deaths worldwide by July 9, 2020.1 Patients 
with preexisting cardiovascular conditions are particularly at 
risk and have poor prognosis.2 With ACE2 (angiotensin-con-
verting enzyme 2)—the binding and internalization receptor for 
SARS-COV23—being highly expressed in the lung, heart, and 
the cardiovascular system, the heart is a target organ susceptible 
to viral and immune-mediated injury.2,4,5 Emerging data suggest 
that cardiac injury, manifested by cardiac biomarker elevation, 
is detected in a sizable of COVID-19 patients and is associated 
with adverse outcomes and increased mortality.6,7 However, how 
useful cardiac biomarkers are in COVID-19 prognosis and how 
to utilize these markers have not been well defined. This study 
aims to establish the role of cardiac-specific injury or stress bio-
marker and their precise association with COVID-19 mortality, to 
determine their use in prognostic evaluation of risk of death and 
to delineate the relationship of cardiac biomarker rise with other 
inflammatory markers in patients diagnosed with COVID-19.
Methods
Data, Materials, and Code Disclosure Statement
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.
Study Design and Participants
This retrospective multicenter cohort study enrolled patients diagnosed 
as COVID-19 and admitted to 9 hospitals in Hubei Province, China, 
from December 31, 2019 to March 4, 2020. COVID-19 diagnosis 
was confirmed by at least one or both criteria of chest computed to-
mography manifestations and reverse transcription–polymerase chain 
reaction according to the New Coronavirus Pneumonia Prevention 
and Control Program (fifth edition) published by the National Health 
Commission of China and World Health Organization interim guid-
ance.8,9 The study design and procedures were approved by the central 
ethics committees, and all collaborating hospitals either approved the 
study protocol by local ethics committees or accepted the approval 
from the central ethics committee. Individual patient informed consent 
was waived by each ethics committee of participating hospitals.
For the analysis regarding the associations between increased 
cardiac injury markers and the risk of all-cause death of COVID-19, 
patients diagnosed with COVID-19 and having available high-sensi-
tivity cardiac troponin I (hs-cTnI) or CK (creatine phosphokinase)-
MB on admission were enrolled in this study. Participants aged <18 
or >75 years, without complete electronic medical records due to 
transferring, or pregnant were excluded from the study. The primary 
end point was 28-day all-cause mortality, and the time of hospital 
admission was designed as day 0. The increase of serum myocardial 
marker levels and other biochemical markers was defined as above 
the upper limit of normal (ULN) according to local hospital criteria. 
Heart injury status was defined as a serum level of hs-cTnI or CK-
MB above the ULN. Due to variations in the examining instruments, 
laboratory techniques, and regents, different ULNs were applied at 
different hospital sites. To guarantee the accuracy and broad-based 
applicability, the levels of cardiac injury biomarkers were normalized 
and analyzed as relative values to their local ULNs.
Data Collection
The demographic information, preexisting comorbidities, clinical char-
acteristics, chest computed tomography radiological data, laboratory 
data, and clinical outcomes were collected from electronic medical re-
cord data. Clinical characteristics including heart rate, breath rate, fever, 
cough, and dyspnea at the time of admission were analyzed. Laboratory 
measurements including neutrophil count, CRP (C-reactive protein), 
cardiac biomarkers (hs-cTnI, CK-MB, NT-proBNP [N-terminal pro-
B-type natriuretic peptide] or BNP [brain natriuretic peptide], MYO 
[myoglobin], and CK), and inflammatory cytokine IL (interleukin)-6 at 
admission and during hospitalization were extracted and analyzed. The 
unilateral and bilateral lung lesion status was obtained from computed 
tomography images. Personal identifiers of included participants were 
first anonymized and replaced by study ID before data collection. All 
the clinical data were individually reviewed and verified by a team of 
experienced physicians blinded to patient identification.
Statistical Analysis
Data in this study were analyzed using R-3.6.3 (R Foundation for 
Statistical Computing, Vienna, Austria) and SPSS Statistics (version 
23.0; IBM, Armonk, NY). Distribution of myocardial marker levels 
(normalized to ULN) by age and sex was displayed using kernel den-
sity estimation. Dynamic change of myocardial marker levels in the cu-
mulative proportions of patients was created and smoothed by locally 
weighted regression and smoothing scatterplots. The Akaike informa-
tion criterion scores and P values were calculated by the univariate lo-
gistic regression analysis to estimate the associations of variables with 
28-day all-cause death of COVID-19 and were examined by the mul-
tivariate Cox analysis to evaluate the quality of the model. A mixed-
effects Cox model analysis was conducted to determine the association 
between baseline myocardial marker levels and the risk of the primary 
end point of COVID-19 by treating the site as a random effect. Hazard 
ratios (HRs) and 95% confidence interval (CI) were calculated in the 
mixed-effects model. Multivariable adjustment included age, sex, and 
preexisting comorbid conditions (diabetes mellitus, hypertension, 
coronary heart disease, and cerebrovascular disease). Kaplan-Meier 
method was applied to compare the cumulative survival between par-
ticipants with normal versus increased myocardial marker levels and 
between those with myocardial marker levels under or above cutoffs. 
The receiver operating characteristic analysis was conducted to assess 
the overall performances of increased levels of myocardial injury 
parameters for identification of the risk of mortality in patients with 
COVID-19. The area under the receiver operating characteristic curve 
(AUC) was computed for evaluating the performance of each marker 
level. A 2-sided α-error <0.05 was considered statistically significant.
Results
Participants and Clinical Characteristics
A total of 7106 participants diagnosed with COVID-19 admit-
ted to 9 hospitals in Hubei Province, China, were recruited 
initially in this study. Of these, 277 cases were excluded due 
to incomplete electronic medical records during interhospi-
tal transfer, 767 patients were excluded due to age limitation 
of the study design (>75 or <18 years), and 29 cases were 
excluded due to pregnancy. In the remaining patients, 3219 
participants had measured CK-MB or hs-cTnI levels, while 
2814 cases were not. The clinical symptoms, basic comorbidi-
ties, laboratory data, and outcomes of those patients are shown 
in Table 1 and Table S1 in the Data Supplement. Compared 
with patients without cardiac injury biomarker measurement, 
patients with biomarker values were older (median age, 57 
[interquartile range, 45–66] versus 54 [interquartile range, 
42–64] years) and had higher percentages of preexisting 
comorbidities and more severe symptoms (Tables S1 and S2). 
The frequencies for increase of hs-cTnI, CK-MB, (NT-pro)
BNP (BNP or NT-proBNP), CK, and MYO were 6.5%, 5.1%, 
12.9%, 12.1%, and 12.0% on admission among patients 
with available cardiac biomarker values, respectively. The 
exact values and normal ranges of laboratory examinations 
in patients with and without myocardial biomarker measure-
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The distribution of age- and sex-specific myocardial bio-
marker profiles relative to those of ULN at presentation were 
analyzed and presented as kernel density plots (Figure S1). The 
age brackets were divided into 18 to 44, 45 to 59, and 60 to 
75 years. The distributions of CK-MB, CK, and MYO showed 
higher levels in men than in women among all 3 age brackets, 
while hs-cTnI and (NT-pro)BNP had comparable distributions 
between male and female patients at the time of admission.
Association of Cardiac Biomarkers With 28-Day 
Mortality of COVID-19
To evaluate associations between outcomes of COVID-19 and 
covariates including cardiac injury markers, we performed 
univariate logistic regression analysis where the Akaike 
Information Criterion and P values were calculated. Notably, 
all 5 myocardial biomarkers (hs-cTnI, CK-MB, (NT-pro)BNP, 
CK, and MYO) were significantly associated with 28-day all-
cause death of COVID-19 (Table S4).
To evaluate the association of each myocardial marker eleva-
tion above laboratory-defined ULN with the primary end point 
of all-cause mortality at 28 days post-admission, we conducted a 
mixed-effects Cox model analysis using the patient’s hospital site 
as a random effect. Multivariables adjustments included age, sex, 
and coexisting comorbidities (hypertension, diabetes mellitus, 
coronary heart disease, and cerebrovascular disease). Adjusted 
HRs for associations of 28-day all-cause mortality of COVID-
19 with abnormally elevated hs-cTnI, CK-MB, NT-proBNP, 
CK, and MYO were shown in Table 2, with 95% CI. Elevation 
of hs-cTnI exhibited the highest adjusted HR of 7.12 ([95% CI, 
4.60–11.03] P<0.001), followed by (NT-pro)BNP of 5.11 ([95% 
CI, 3.50–7.47] P<0.001), CK-MB of 4.86 ([95% CI, 3.33–7.09] 
P<0.001), and MYO of 4.50 ([95% CI, 3.18–6.36] P<0.001). 
Total CK—a much less specific cardiac biomarker—had an 
adjusted HR of 3.56 ([95% CI, 2.53–5.02] P<0.001).
Kaplan-Meier curves illustrated that patients with 
increased hs-cTnI, CK-MB, (NT-pro)BNP, CK, and MYO 
had significantly decreased survival rate compared with those 
with normal levels (Figure 1). The Kaplan-Meier curves dem-
onstrated an early separation of the mortality curves between 
patients showing elevated admission biomarker values above 
ULN, versus those having normal values, underscoring the 
rapid onset of death among the high-risk group of COVID-19 
patients. This was particularly prominent for cardiac-specific 
biomarkers, such as hs-cTnI, CK-MB, and (NT-pro)BNP.
Compared with patients without available myocardial bio-
markers, patients with measured cardiac injury markers had 
higher incidences of 28-day all-cause death and the occur-
rences of Acute Respiratory Distress Syndrome, heart failure, 
Table 1. Baseline Characteristics of Patients With COVID-19
 Parameters With Biomarkers (n=3219) Without Biomarkers (n=2814) P Value
Age, y; median (IQR) 57 (45–66) 54 (42–64) <0.001
Men, n (%) 1535 (47.7) 1324 (47.1) 0.640
Women, n (%) 1684 (52.3) 1490 (53.0) 0.640
Heart rate, bpm; median (IQR) 84 (78–95) 80 (76–92) <0.001
Respiratory rate, bpm; median (IQR) 20 (19–21) 20 (18–21) 0.039
SBP>140, mmHg; n/N (%) 543/2753 (19.7) 358/2224 (16.1) 0.001
Fever, n (%) 2332 (72.4) 1970 (70.0) 0.039
Cough, n (%) 2118 (65.8) 1815 (64.5) 0.304
Dyspnea, n (%) 650 (20.2) 432 (15.4) <0.001
Comorbidities
  Hypertension, n (%) 895 (27.8) 634 (22.5) <0.001
  Diabetes mellitus, n (%) 413 (12.8) 256 (9.1) <0.001
  Coronary heart disease, n (%) 206 (6.4) 100 (3.6) <0.001
  Cerebrovascular disease, n (%) 74 (2.3) 37 (1.3) 0.006
Radiological characteristics
   Unilateral lung lesion, n/N (%) 292/2995 (9.8) 298/2564 (11.6) 0.027
   Bilateral lung lesion, n/N (%) 2558/2995 (85.4) 2057/2564 (80.2) <0.001
Laboratory examinations
   Hs-cTnI increase, n/N (%) 95/1462 (6.5) … …
   CK-MB increase, n/N (%) 158/3120 (5.1) … …
   BNP or NT-proBNP increase, n/N (%) 213/1650 (12.9) 69/336 (20.5) <0.001
   CK increase, n/N (%) 307/2534 (12.1) 61/645 (9.5) 0.070
   MYO increase, n/N (%) 228/1895 (12.0) 9/57 (15.8) 0.516
BNP indicates brain natriuretic peptide; CK, creatine phosphokinase; COVID-19, coronavirus disease 2019; hs-cTnI, high-sensitivity cardiac 
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disseminated intravascular coagulation (DIC), sepsis, or multi-
organ failure and acute renal failure (Table S5). However, there 
were no significant differences in the main causes of death be-
tween these 2 subcohorts (Table S6). These data suggested that 
heart injury markers might sensitively respond to SARS-CoV-2 
infection or infection-related outcomes.
Prognostic Performance of Cardiac Injury 
Biomarkers in Predicting 28-Day All-Cause 
Mortality of COVID-19
To compare the relative accuracy, sensitivity, specificity, 
and positive and negative predictive values of each bio-
marker based on laboratory-defined ULN, the prognostic 
performance of each marker was analyzed. The receiver 
operating characteristic curve was used to demonstrate the 
ability of each cardiac biomarker in discrimination of high 
risk of COVID-19 mortality, which was quantitated as AUC. 
Increase of MYO—an early release biomarker of cardiac 
injury—showed the highest overall performance (AUC, 
0.83 [95% CI, 0.80–0.86]) to predict the risk of COVID-19 
mortality, followed by (NT-pro)BNP (AUC, 0.81 [95% CI, 
0.78–0.85]), hs-cTnI (AUC, 0.78 [95% CI, 0.73–0.84]), and 
CK-MB (AUC, 0.71 [95% CI, 0.67–0.75]). CK had the low-
est performance (AUC, 0.67 [95% CI, 0.62–0.72]; Table 3; 
Figure S2). It is useful to note that the overall negative 
Table 2. Association of Increased Cardiac Injury Markers Above the Upper Limit of Normal With 28-d All-Cause Mortality of COVID-19
Crude Model 1
HR (95% CI) P Value HR (95% CI) P Value
Hs-cTnI 9.59 (6.36–14.47) <0.001 7.12 (4.60–11.03) <0.001
CK-MB 5.30 (3.71–7.59) <0.001 4.86 (3.33–7.09) <0.001
(NT-pro)BNP 5.62 (3.99–7.93) <0.001 5.11 (3.50–7.47) <0.001
CK 4.31 (3.13–5.92) <0.001 3.56 (2.53–5.02) <0.001
MYO 6.84 (4.95–9.45) <0.001 4.50 (3.18–6.36) <0.001
Model 1: Adjusted for age, sex, and coexisting diseases (diabetes mellitus, hypertension, coronary heart disease, and cerebrovascular disease). 
CK indicates creatine phosphokinase; COVID-19, coronavirus disease 2019; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I; MYO, 
myoglobin; and (NT-pro)BNP, N-terminal pro-B-type natriuretic peptide or brain natriuretic peptide.
Figure 1. Survival profiles of COVID-19 patients 
stratified according to cardiac biomarkers. 
Kaplan-Meier curves showing cumulative 
survival of coronavirus disease 2019 (COVID-19) 
patients with increased or normal levels of high-
sensitivity cardiac troponin I (hs-cTnI; A), CK 
(creatine phosphokinase)-MB (B), (NT-pro)BNP 
(N-terminal pro-B-type natriuretic peptide or 
brain natriuretic peptide; C), MYO (myoglobin; 
D), and CK (E) during a 28-d follow-up. The 
increase of myocardial marker represents level 
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predictive values are uniformly high for any of these bio-
markers, at over 96% for all of those evaluated.
The standard laboratory cutoff value of ULN is usually 
defined as the 99th upper percentile of biomarker distribu-
tion in the normal population. However, our data indicated 
that the operational cutoff based on the biomarker distribu-
tion and receiver operating characteristic performance curve 
should be redefined for each of the biomarkers to enhance 
the prognostic sensitivity of the biomarkers. Indeed, the op-
erational cutoff values of hs-cTnI, CK-MB, (NT-pro)BNP, 
CK, and MYO for COVID-19 mortality prediction were 
markedly lower, calculated at 49.0%, 49.1%, 18.9%, 44.8%, 
and 49.8% of their respective ULNs. Notably, using these 
cutoff values of each myocardial marker in this risk predic-
tion model improved the balanced accuracy versus using the 
currently recommended ULN values (0.77 versus 0.66 for 
hs-cTnI, 0.66 versus 0.59 for CK-MB, 0.75 versus 0.66 for 
(NT-pro)BNP, 0.75 versus 0.69 for MYO, and 0.64 versus 
0.63 for CK) than using the current ULN values defined in 
the laboratory (Table 3; Table S7).
Accordingly, patients with biomarker levels above each 
recalibrated cutoff were at a significantly higher risk of 28-day 
all-cause mortality of COVID-19, compared with those under 
the cutoff points (Figure S3). After adjusted for age, sex, and 
comorbidities in the mixed-effects Cox model and treated hos-
pital site as a random effect, patients with elevated myocar-
dial biomarkers over the new cutoffs were at a significantly 
higher risk of mortality than those having biomarker levels 
under cutoff values with adjusted HR of 10.68 ([95% CI, 
6.87–16.59] P<0.001) for hs-cTnI, 3.63 ([95% CI, 2.60–5.06] 
P<0.001) for CK-MB, 12.01([95% CI, 6.39–22.58] P<0.001) 
for (NT-pro)BNP, 2.7 ([95% CI, 1.92–3.81] P<0.001) for CK, 
and 5.00 ([95% CI, 3.37–7.42] P<0.001) for MYO (Table S8).
To address the potential selection bias, we further 
adjusted for the imbalanced variables related to disease se-
verity (CRP increase, neutrophil count increase, lymphocyte 
count decrease, d-dimer increase, and Spo
2
 <95%) between 
patients with or without increased heart injury markers above 
cutoff values in the mixed-effects Cox model. The results 
showed that the increased hs-cTnI (adjusted HR, 4.74 [95% 
CI, 3.05–7.35]; P<0.001), CK-MB (adjusted HR, 2.17 [95% 
CI, 1.56–3.01]; P<0.001), CK (adjusted HR, 1.80 [95% CI, 
1.28–2.53]; P<0.001), (NT-pro)BNP (adjusted HR, 5.67 
[95% CI, 2.97–10.82]; P<0.001), and MYO (adjusted HR, 
2.74 [95% CI, 1.82–4.13]; P<0.001) were still significantly 
associated with higher risk of all-cause mortality of COVID-
19 (Table S8). The Akaike information criterion values of the 
crude and adjusted analysis model were shown in Table S9, 
among which the model adjusted for age, sex, and comorbid-
ities had relatively low Akaike information criterion values 
for each myocardial marker.
We further performed a subgroup sensitivity analysis using 
patients in site 1, site 2, site 3, and site 6, where a relatively 
high percentage of patients had CK-MB or hs-cTnI measured 
(70.0% in site 1 and site 2, 82.8% in site 3, and 68.3% in site 
6). In the mixed-effects Cox model, after adjusting for age, 
sex, and coexisting comorbidities, the significant associations 
between increased cardiac injury biomarkers and a higher risk 
of COVID-19 mortality were still maintained with adjusted 
HR of 4.42 ([95% CI, 2.74–7.13] P<0.001) for hs-cTnI, 2.98 
([95% CI, 1.94–4.59] P<0.001) for CK-MB, 5.46 ([95% 
CI, 2.55–11.73] P<0.001) for (NT-pro)BNP, 1.57 ([95% CI, 
1.00–2.45] P=0.048) for CK, and 2.92 ([95% CI, 1.76–4.85] 
P<0.001) for MYO.
In another sensitivity analysis, we excluded patients with 
acute myocardial infarction to mitigate heart disease history-
related potential confounders. After adjusting for age, sex, 
and comorbidities, the increased CK-MB (adjusted HR, 4.39 
[95% CI, 2.94–6.56]; P<0.001), hs-cTnI (adjusted HR, 6.95 
[95% CI, 4.48–10.8]; P<0.001), CK (adjusted HR, 3.45 [95% 
CI, 2.43–4.90]; P<0.001), (NT-pro)BNP (adjusted HR, 4.88 
[95% CI, 3.31–7.20]; P<0.001), and MYO (adjusted HR, 4.20 
[95% CI, 2.94–6.00]; P<0.001) remained to be significantly 
associated with higher risk of all-cause mortality of COVID-
19 in this subcohort.
More importantly, the patients with cardiac biomarker lev-
els ranging from the newly established cutoffs to laboratory 
reference ULNs still showed significantly lower percentage 
Table 3. Overall Performance of Cardiac Biomarkers for Predicting COVID-19 Mortality According to Receiver Operating Characteristic Curves
Parameters Hs-cTnI CK-MB (NT-pro)BNP CK MYO CRP D-Dimer
n 1462 3120 1650 2534 1895 1489 1913
Mortality 98 178 133 163 148 123 154
AUC (95% CI) 0.78 (0.73–0.84) 0.71 (0.67–0.75) 0.81 (0.78–0.85) 0.67 (0.62–0.72) 0.83 (0.80–0.86) 0.81 (0.77–0.85) 0.81 (0.77–0.84)
Cutoff (relative to ULN) 0.490 0.491 0.189 0.448 0.498 6.545 1.126














Sensitivity, % 63.27 60.67 91.73 64.42 75.00 81.30 74.68
Specificity, % 91.06 71.82 58.80 64.24 75.62 66.25 72.26
PPV 0.34 0.12 0.16 0.11 0.21 0.18 0.19
NPV 0.97 0.97 0.99 0.96 0.97 0.98 0.97
Balanced accuracy 0.77 0.66 0.75 0.64 0.75 0.74 0.73
AUC indicates area under the receiver operating characteristic curves; CK, creatine phosphokinase; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; 
hs-cTnI, high-sensitivity cardiac troponin I; MYO, myoglobin; NPV, negative predictive value; (NT-pro)BNP, N-terminal pro-B-type natriuretic peptide or brain natriuretic 
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survival than those with marker levels below the newly estab-
lished cutoff values (Figure 2). The adjusted HRs for 28-day 
all-cause death of patients with cardiac biomarker between 
cutoffs and ULNs were 8.54 ([95% CI, 4.99–14.63] P<0.001) 
for hs-cTnI, 2.87 ([95% CI, 1.99–4.14] P<0.001) for CK-MB, 
8.70 ([95% CI, 4.50–16.82] P<0.001) for (NT-pro)BNP, 3.55 
([95% CI, 2.20–5.73] P<0.001) for MYO, and 1.71 ([95% CI, 
1.14–2.58] P=0.009) for CK compared with those with marker 
levels below cutoffs (Table 4). This means patients with even 
borderline levels of biomarker (between ULN and the newly 
established cutoffs) as defined by our current study might still 
have a higher risk of 28-day mortality.
Overall, we found the number of patients showing bio-
markers above the newly established cutoff values but below 
the laboratory-defined ULNs at admission were 89 for hs-
cTnI, 779 for CK-MB, 533 for (NT-pro)BNP, 308 for MYO, 
and 646 for CK (Figure 2). These data revealed that the prev-
alence of cardiac injury might be substantially underestimated 
by the current laboratory-defined ULN values.
Trajectory Patterns of Cardiac Biomarkers and 
Inflammatory Factor Elevation in Patients With 
COVID-19
To further demonstrate the mechanistic cause of cardiac injury 
in COVID-19 patients, we determined the temporal relationship 
of cardiac biomarker elevation with that of the inflammatory 
markers over time, we analyzed the cumulative proportions of 
patients with increased cardiac biomarkers in association with 
inflammatory factors of CRP, neutrophil count, and IL-6 ele-
vation during the entire study period. This was based on the 
laboratory-defined ULN and analyzed from time of symptom 
onset (day 0) to the end of follow-up, as illustrated in Figure S4.
Among the patients without signs of heart injury (defined 
by having elevated hs-cTnI or CK-MB above their ULN), the 
increases of inflammatory markers were lower and slower 
than those with heart injury (Figure S4A). In patients showing 
heart injury during the entire hospitalization, neutrophil per-
centage and CRP were rapidly and simultaneously increased 
after disease onset, immediately followed by the increases of 
CK-MB, MYO, and hs-cTnI. In contrast, the significant eleva-
tion of IL-6 occurred only after the increases of these myocar-
dial markers and was highly elevated mainly in patients with 
evidence of cardiac injury (Figure S4A).
We further divided patients into poor outcome and favor-
able outcome groups according to the occurrence of death, in-
tensive care unit treatment, and mechanical ventilation from 
admission to the end of follow-up, where patients with any 
one of the above events were classified as in poor outcome and 
patients without any of the above events were in favorable out-
come group. The temporal patterns of myocardial biomarkers 
and inflammatory factors were cosegregated between these 2 
groups (Figure S4B). Compared with patients with favorable 
outcomes, the increases of neutrophil percentage and CRP 
showed sharper slope in patients with poor outcome. The pro-
portion of patients with increased hs-cTnI was significantly 
higher in the poor outcome than in the favorable outcome 
Figure 2. The percentage survival of patients 
with cardiac biomarker levels under cutoffs, 
between cutoffs and upper limits of normal 
(ULNs), and above ULNs of high-sensitivity 
cardiac troponin I (hs-cTnI; A), CK (creatine 
phosphokinase)-MB; B), (NT-pro)BNP 
(N-terminal pro-B-type natriuretic peptide or 
brain natriuretic peptide); C), MYO (myoglobin; 
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group. Patients with minimum levels of (NT-pro)BNP had 
overall a much more favorable outcome. Notably, the elevation 
of serum IL-6 level was highly prognostic of poor outcome and 
followed slightly behind cardiac biomarker elevation such as 
hs-cTnI in patients with poor outcome. In contrast, the increase 
of IL-6 was significantly delayed and blunted in amplitude in 
those with favorable outcome (Figure S4B). Furthermore, the 
magnitudes of the inductions in both myocardial markers and 
inflammatory factors were higher in the poor outcome patients 
than in the ones with favorable outcome (Figure S5).
The increased inflammatory marker (CRP) and coagu-
lation marker (d-dimer) levels were also significantly asso-
ciated with an increased risk of 28-day all-cause mortality 
of COVID-19 and had interactive effects with cardiac in-
jury markers in predicting the poor outcomes of COVID-19 
(Table 3; Table S10).
Discussion
This retrospective study is a comprehensive evaluation of serum 
cardiac biomarkers with respect to 28-day all-cause mortality of 
COVID-19. We demonstrated that elevations of biomarkers such 
as hs-cTnI, CK-MB, (NT-pro)BNP, or MYO based on refer-
ence laboratory normal cutoff values were highly prognostic of 
28-day all-cause mortality, including deaths occurring soon after 
admission. However, standard cutoff values currently used for 
diagnosis likely underestimated the true extent of cardiac injury. 
The newly established cutoffs in our study for COVID-19 prog-
nosis were much lower than the currently accepted laboratory 
cutoff thresholds (by about 50%). Dynamic pattern of cardiac 
biomarker elevation showed their onset coincided with CRP and 
neutrophil elevation but preceded the elevation of IL-6.
These findings are consistent with earlier reports that car-
diac injury biomarkers are associated with an increased risk 
of COVID-19 mortality.7,10 Elevated levels of cardiac troponin 
I and (NT-pro)BNP, CK-MB, and MYO are also associated 
with more severe symptoms and disease progression.11–14 Our 
larger sample size helped to better define and to improve the 
performance characteristics of these biomarkers for COVID-
19, which manifest with widely divergent outcomes from full 
recovery to rapid death. The cardiac-specific biomarkers, such 
as hs-cTnI, CK-MB, and (NT-pro)BNP, generally have bet-
ter performance than nonspecific markers such as CK. The 
lower levels of newly established cutoff values of cardiac in-
jury markers further suggest that the currently used laboratory 
ULNs for these markers, based on the 99 percentiles of distri-
bution in a normal population, might significantly underesti-
mate the extent of cardiac injury associated with COVID-19.
The ULNs of cardiac injury markers are primarily estab-
lished and extensively recognized for diagnosis of the severity 
of the cardiac injury and thus would have the satisfactory 
Table 4. Association of Cardiac Injury Markers With 28-d All-Cause Mortality of COVID-19 in Patients Divided by Cutoffs and Upper Limit of Normal
Crude Model 1
HR (95% CI) P Value HR (95% CI) P Value
Hs-cTnI
  ≤Cutoff Reference  Reference  
  Cutoff−ULN 11.33 (6.84–18.77) <0.001 8.54 (4.99–14.63) <0.001
  >ULN 15.50 (9.76–24.61) <0.001 12.85 (7.79–21.19) <0.001
CK-MB
  ≤Cutoff Reference  Reference  
  Cutoff−ULN 2.67 (1.92–3.72) <0.001 2.87 (1.99–4.14) <0.001
  >ULN 7.72 (5.20–11.46) <0.001 6.81 (4.40–10.54) <0.001
(NT-pro)BNP
  ≤Cutoff Reference  Reference  
  Cutoff−ULN 10.47 (5.52–19.83) <0.001 8.70 (4.50–16.82) <0.001
  >ULN 24.94 (13.07–47.59) <0.001 22.72 (11.38–45.36) <0.001
CK
  ≤Cutoff Reference  Reference  
  Cutoff−ULN 1.80 (1.22–2.66) 0.003 1.71 (1.14–2.58) 0.009
  >ULN 5.35 (3.73–7.68) <0.001 4.79 (3.18–7.22) <0.001
MYO
  ≤Cutoff Reference  Reference  
  Cutoff−ULN 4.53 (2.91–7.04) <0.001 3.55 (2.20–5.73) <0.001
  >ULN 11.49 (7.73–17.07) <0.001 7.12 (4.60–11.02) <0.001
Model 1: Adjusted for age, sex, and coexisting diseases (diabetes mellitus, hypertension, coronary heart disease, and cerebrovascular disease). 
CK indicates creatine phosphokinase; COVID-19, coronavirus disease 2019; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I; MYO, 
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performance for predicting the prognosis of patients with car-
diovascular diseases. Therefore, it is interesting that outcomes 
from COVID-19—a disease associated primarily with the 
lung—are also well predicted by cardiac biomarkers. While 
the inherent limitation of a retrospective study makes it impos-
sible to demonstrate the causal effect of increased cardiac injury 
markers with COVID-19 death, the performance of these mark-
ers for predicting COVID-19 prognosis may indicate patholog-
ical impact of SARS-CoV-2 infection or the infection-related 
pathogenesis on myocardium. In consistence with this hypo-
thesis, Angeli et al found a wide spectrum of ECG abnormali-
ties during hospitalization, including persistent ST-T changes, 
atrial fibrillation, and brady-tachy syndrome, in a prospective 
study containing 50 inpatients with COVID-19. Among those 
with abnormal electrocardiogram performance, 38% of them 
were recorded with abnormal serum levels of hs-cTnI.15
Heart injury may likely involve multiple mechanisms, in-
cluding primary injury from SARS-COV-2 infection and in-
direct injury from the imbalanced immune response with 
dominant macrophage and neutrophil effects. This can be aug-
mented further by systemic or cardiac hypoxemia and micro-
angiopathy and microthormbi.2 ACE2—the functional receptor 
and a portal of entry for both SARS-COV and SARS-COV-2—
is highly expressed in the heart and vasculature.3,16,17 Previous 
studies indicated that SARS-COV is detectable in the heart of 
infected patients18 and ACE2 expression is downregulated after 
coronavirus infection, leading to excessive activation of the 
renin-angiotensin-aldosterone system, which can further exacer-
bate myocardial injury.19,20 The link between SARS-COV-2 and 
ACE2 provides a possible mechanism that SARS-COV-2 binds 
to ACE2 expressed on cardiomyocytes/fibroblasts and induces 
ACE2 downregulation and renin-angiotensin-aldosterone 
system dysfunction, which in turn leads to heart dysfunction and 
pneumonia progression. Our most recent study indicated that 
inpatients using ACE inhibitors or angiotensin II receptor block-
ers are at significantly lower risk of 28-day all-cause death com-
pared with nonusers in patients with hypertension hospitalized 
with COVID-19.21 Autopsy analysis of hearts from COVID-19 
patients suggested a potential involvement of systematic in-
flammation in heart injury.22 However, there are, so far, no data 
directly demonstrating the presence of SARS-CoV-2 within my-
ocardial tissue or the direct influence of renin-angiotensin-aldo-
sterone system inhibitors on heart injury in COVID-19 patients.
There are several limitations of our study. First, the inherent 
limitations of retrospective studies make it impossible to deter-
mine whether cardiac injury is the causal effect on the prognosis 
of COVID-19. Second, the cutoffs of cardiac injury markers in 
predicting COVID-19 outcomes were established based on a 
Chinese population, which will require further external valida-
tions from other independent cohorts. Third, in the urgent cir-
cumstances during the COVID-19 pandemic, not all markers 
and examinations (eg, electrocardiogram, ultrasound computed 
tomography and magnetic resonance imaging) related to heart 
injury were fully performed and collected during the entire hos-
pitalization period from all participants. The incomplete data 
collection in multiple sites might lead to confounding effects on 
the magnitude of the association between cardiac injury mark-
ers and COVID-19 prognosis and the predicting performance 
of those markers for COVID-19 death. Fourth, because of the 
limited sample size, it is unknown whether those myocardial 
markers are also effective in predicting the outcomes of COVID-
19 in patients with different complications or comorbidities. 
Fifth, as all participants involved in this study were inpatients, 
findings in this study might not be fully applicable to all indi-
viduals in the general population infected with SARS-COV-2, 
such as outpatients in isolation sites or community. Sixth, there 
might be selection bias of the study subjects because myocar-
dial markers may be examined more frequently in patients with 
suspected heart injury or with signs of cardiovascular diseases 
than in the general patient population. The imbalanced history of 
heart failure, the time point of admission, and the availability of 
medical resources might also introduce confounding factors into 
our conclusion. Thus, associations between cardiac biomarkers 
and COVID-19 mortality and the exact cutoffs of those markers 
for COVID-19 prognosis with adequate sensitivity and speci-
ficity in the whole patient population need to be further inves-
tigated in large-scale general population and in the rigorously 
designed prospective studies and randomized controlled trials.
In conclusion, the abnormal cardiac biomarker pattern in 
COVID-19 patients was significantly associated with increased 
mortality risk, and the newly established COVID-19 prog-
nostic cutoff values of hs-cTnI, CK-MB, (NT-pro)BNP, CK, 
and MYO were found to be much lower (≈50%) than reference 
upper normal limits for the general population. It is clinically 
meaningful that the fluctuating levels of myocardial biomark-
ers should be intensively monitored, and patients with elevated 
levels of those biomarkers should be intervened timely to im-
prove the prognosis of COVID-19. Our findings support addi-
tional prospective studies and randomized controlled clinical 
trials to accurately validate the risk thresholds and exact impact 
of myocardial injury for individuals with COVID-19.
Perspectives
To properly evaluate patients with COVID-19 at admission, the 
cutoff threshold of abnormality for hs-cTnI, CK-MB, (NT-pro)
BNP, CK, and MYO at admission should be lower than the cur-
rently recommended laboratory range. Using standard reference 
laboratory cutoffs might underestimate the extent of cardiac in-
jury. Measurement of cardiac-specific biomarkers and proper in-
terpretation on admission can help to identify COVID-19 patients 
with a high-risk trajectory. The elevations can help to provide ref-
erences for the management, monitoring, and enrollment for pro-
spective studies and randomized controlled clinical trials.
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What Is New?
•	Heart injury is one of the major complications in patients with coronavi-
rus disease 2019 (COVID-19).
•	However, the prognostic power of cardiac biomarkers, their utility, and 
pattern of release in COVID-19 patients have not been clearly defined.
What Is Relevant?
•	This multicentered retrospective cohort study involving 3219 patients 
demonstrated that hazard ratios for admission cardiac biomarkers such 
as high-sensitivity cardiac troponin I, CK (creatine phosphokinase)-MB, 
or (NT-pro)BNP (N-terminal pro-B-type natriuretic peptide or brain natri-
uretic peptide) for 28-d mortality is high at between 4 and 7 folds.
•	The established cutoff values of each cardiac biomarker to predict the 
risk of COVID-19 mortality are actually much lower than standard refer-
ence laboratory cutoffs by being about 50% lower.
•	Trajectory analysis showed cardiac injury biomarkers are elevated early 
in course of disease, being parallel to CRP (C-reactive protein) and neu-
trophil rise, but precedes rise in IL (interleukin)-6 and predicts mortality, 
ventilator use, and intensive care unit admission.
Summary
To properly prognosticate patients with COVID-19 at admission, the 
cutoff threshold of abnormality for high-sensitivity cardiac troponin 
I, CK-MB, (NT-pro)BNP, CK, and MYO (myoglobin) was analyzed as 
about 50% lower for most of the markers. Using standard reference 
laboratory cutoffs might underestimate the extent of cardiac injury. 
Admission cardiac biomarkers are sensitively prognostic for impend-
ing mortality in COVID-19. Their elevation tracks CRP and neutrophil 
rise but precedes IL-6 elevation. Measurement of cardiac-specific 
biomarkers and proper interpretation on admission can help to iden-
tify COVID-19 patients with a high-risk trajectory. The elevations pro-
vide support to guide management, monitoring, and enrollment into 
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